La Cisplatine Dans la Prise en Charge des Cancers ORL en Concomitant avec la Radiothérapie

Abstract

Upper aero digestive tract cancer (ORL) represents a major global public health issue, closely linked to smoking, alcohol consumption, and other risk factors. Early detection, prevention, and multimodal treatments are essential to improve clinical outcomes and reduce the burden of this disease. Currently, RADPLAT is the most commonly used therapeutic strategy in the management of ORL cancer. In this study, we explored the efficacy and safety of cisplatin when used in combination with radiotherapy. By examining data from several clinical studies that highlighted the importance of this approach in managing these cancers, we found that the combination of cisplatin with radiotherapy leads to a significant improvement in tumor response rate and patient survival. Furthermore, these studies addressed the challenges associated with this therapeutic combination, such as treatmentrelated side effects and toxicity. In summary, our work underscores the crucial role of cisplatin in the multimodal treatment of ORL cancer, while also highlighting the need for further studies on the use of RADPLAT in the management of ORL cancers. In doing so, we contribute to the advancement of knowledge and improvement of patient care.